Can MRGPRX2 inhibition prevent migraine? Evommune’s EVO756 enters Phase 2b study
Evommune begins a Phase 2b EVO756 migraine trial after a urticaria setback, testing whether MRGPRX2 inhibition can deliver preventive benefit.
Pharma & Biotech
Pharma & Biotech
Can Evommune turn EVO756 into a cross-indication inflammatory franchise with migraine next?
Evommune is taking EVO756 into migraine prophylaxis. Read why MRGPRX2 inhibition could matter, and what risks still cloud the story.